This action-packed two day agenda holds 13 Presentations from industry and academic leaders, 2 interactive panel/roundtable discussions, one interactive HCC workshop and over 4 hours of networking, you can join the only platform discussing issues present in the development of curative HBV therapeutics.
Join this critical global forum which will again be uniting industry specialists from Pharma, Biotechs, Academia and Solution Providers as we target the most pressing issues important to bringing the next generation HBV drugs to market.
Conference Pass (early birds also available): USD 1999.0
Speakers: Eduardo Bruno Martins | Vice President - Clinical Development | Abbvie, Yuchun Nie | Senior scientist | Aligos Therapeutics, Gaston Picchio | Chief Development Officer | Arbutus Biopharma, Jinzi Wu | Founder, Chairman and Chief Executive Officer | Ascletis Inc, William Delaney | Chief Scientific Officer | Assembly Biosciences (USA), Stephane Daffis | Scientist II | Gilead Sciences, Yong-Yuan Zhang | Founder and Chief Science Officer | HBVtech, Melissa Palmer | Chief Medical Officer | Gannex Pharma Ltd. A wholly owned subsidiary of Ascletis Pharma LLC, Chari Cohen | Senior Vice President | Hepatitis B Foundation, Paul Desmond | Coordinator | Hepatitis B Positive Trust, Marco Lepore | Head of Discovery Research | Immunocore Ltd, Patricia Mendez | Vice President - Clinical Development | Immunocore Ltd, Sarah Leonard | Group Leader | Immunocore Ltd., Andrew Vaillant | Chief Scientific Officer | Replicor Inc., David Anderson | Chief Scientific Officer | VBI Vaccines Inc., Stephan Urban | Professor | University Hospital of Heidelberg, Haitao Guo | Professor | University of Pittsburgh, Tom Evans | Chief Scientific Officer | Vaccitech
Time: 09:00 - 17:00